ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare
Generics BulletinLupin and Zentiva have announced a license and supply agreement for the commercialization of Lupin’s Cimzia (certolizumab pegol) biosimilar “across multiple markets globally.” “Zentiva will oversee co
Generics BulletinFresh from declaring that it had received “very strong feedback” from global partners interested in licensing rights to new assets in the company’s pipeline, Alvotech has struck a fresh commercializat
Generics BulletinKashiv BioSciences and its commercialization partners have announced positive topline data from a Phase III confirmatory trial investigating the omalizumab biosimilar rival to Genentech/Novartis’ Xola